Zanamivir

I think I have the flu. Should I ask my GP for antivirals?

Retrieved on: 
Tuesday, August 29, 2023

If you test positive for COVID and you’re eligible for antivirals, you’ll likely ask your GP for a script to protect you from severe disease.

Key Points: 
  • If you test positive for COVID and you’re eligible for antivirals, you’ll likely ask your GP for a script to protect you from severe disease.
  • So when should you make the effort to see a GP for a prescription for influenza antivirals?

What exactly is influenza?


    The flu is primarily a viral infection of the respiratory system that can spread through sneezing, coughing, or touching contaminated objects then touching your nose or mouth. Common symptoms include headache, sore throat, fever, runny or blocked nose and body aches that last a week or more. Influenza is actually a group of viruses, divided into several sub-groups. Flu A and B are the most common groups that circulate in humans.

What are flu antivirals?

    • Most flu antivirals target neuraminidase, an important enzyme the virus uses to release itself from cells.
    • On the other hand, COVID antivirals work by inhibiting other parts of the viral life cycle involved in the virus replicating itself.
    • Read more:
      Should I get a flu vaccine this year?

How effective are antivirals for the flu?

    • Antivirals have the greatest effect if started 24-72 hours after symptoms.
    • In a study from the 2009 swine flu (H1N1) pandemic in the United States, treatment with antivirals (Tamiflu and Relenza) reduced the chance of needing to be hospitalised.
    • The research is less clear about whether antivirals prevent the development of flu complications such as secondary bacterial pneumonia.

Are flu antivirals becoming less effective?

    • The impact of the antiviral resistance is unclear but there is evidence indicating resistant strains can uphold their ability to replicate effectively and spread.
    • However, government agencies and surveillance programs are constantly monitoring the spread of antiviral resistance.

Antivirals can also prevent the flu if you’ve been exposed

    • Tamiflu and Relenza can also be used to prevent flu infections, if we’re exposed to the virus or come into contact with infected people.
    • Some studies suggest Tamiflu and Relenza can reduce the chance of developing symptomatic influenza by 70-90%.

So who should talk to their GP about a prescription?


    Australian guidelines recommend doctors offer antivirals to people with influenza who have severe disease or complications. Doctors can also consider treatment for people at higher risk of developing severe disease from influenza. This includes:
    • Antiviral treatment also can be considered for otherwise healthy symptomatic patients who have confirmed or suspected influenza, if they can start treatment within 48 hours of developing symptoms.
    • In some instances a doctors can make a clinical diagnosis of influenza based on the symptoms and known close flu positive contacts of the patient.
    • Read more:
      What happens in our body when we encounter and fight off a virus like the flu, SARS-CoV-2 or RSV?

PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals

Retrieved on: 
Tuesday, June 1, 2021

PharmaTher and TSRL share the commitment to commercialize a patented hydrogel-forming microneedle patch delivery technology licensed from Queens University of Belfast.

Key Points: 
  • PharmaTher and TSRL share the commitment to commercialize a patented hydrogel-forming microneedle patch delivery technology licensed from Queens University of Belfast.
  • Zanamivir, other antiviral therapeutics and vaccines) in a microneedle patch with the potential to improve on the safety (i.e.
  • TSRL has successfully conducted a pre-IND meeting with the US FDA and achieved agreement with the agency on their proposed 505(b)2 product development plans.
  • PharmaTher is currently conducting an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.

TSRL, Inc. awarded $3M NIH grant to continue development of microneedle patch for treatment of influenza

Retrieved on: 
Thursday, May 28, 2020

The project builds on an initial Phase I Small Business Innovation Research (SBIR) award of $600,000 to optimize microneedle formulations for painless administration of zanamivir through the skin.

Key Points: 
  • The project builds on an initial Phase I Small Business Innovation Research (SBIR) award of $600,000 to optimize microneedle formulations for painless administration of zanamivir through the skin.
  • Influenza, or "the flu," is caused by RNA viruses.
  • It infects birds and mammals and spreads worldwide during seasonal epidemics that result in up to 500,000 deaths every year.
  • Microneedle patches allow for painless administration and can deliver zanamivir over multiple days with a single administration.

FDA Accepts Genentech’s New Drug Application for Xofluza for the Treatment of Influenza in Children

Retrieved on: 
Friday, March 27, 2020

Todays milestone brings us closer to providing single-dose Xofluza to children with influenza, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.

Key Points: 
  • Todays milestone brings us closer to providing single-dose Xofluza to children with influenza, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
  • We also look forward to working with the FDA to incorporate Xofluza as a preventive treatment following exposure to influenza.
  • Xofluza tablets are currently approved in many countries around the world for the treatment of influenza types A and B.
  • BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza.

United States Influenza Diagnostic Market Prospects, Trends Analysis, Market Size and Forecasts up to 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 17, 2019

What is the market size of influenza diagnostic market in United States?

Key Points: 
  • What is the market size of influenza diagnostic market in United States?
  • What is the competitive position in United States influenza diagnostic market?
  • What are the opportunities in United States influenza diagnostic market?
  • What are the modes of entering United States influenza diagnostic market?